Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety of Hypromellose-based Nasal Spray Solution Containing Human IgG1 Anti-SARS-CoV-2 Antibody Cocktail in Healthy Volunteers

NCT05358873 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT05358873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05358873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety of Hypromellose-based Nasal Spray Solution Containing Human IgG1 Anti-SARS-CoV-2 Antibody Cocktail in Healthy Volunteers
Lead sponsor
Chulalongkorn University
Phase
Not applicable
Overall status
Completed
Start date
April 20, 2022
Completion date
July 1, 2022
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov 2 infection, sars-cov-2 acute respiratory disease